BioConnection Receives European CMO of the Year Award 2024 in (Bio)pharmaceuticals
BioConnection is excited to share that we’ve been named the European Company of the Year in Biopharmaceutical Contract Manufacturing 2024 by Pharma Tech Outlook. This award means a lot to us because it reflects the trust and recognition we’ve earned from our customers and peers in the industry.
Being acknowledged by an expert panel of C-level executives, industry thought leaders, and the editorial board of Pharma Tech Outlook is a huge honor. It highlights the hard work and dedication of our team in providing top-quality contract manufacturing services.
At BioConnection, we’re passionate about what we do and committed to supporting our clients in bringing innovative therapies to market. This award motivates us to keep pushing forward and continue making a positive impact in the biopharmaceutical sector.
Thank you to everyone who has supported us on this journey. We’re looking forward to achieving even more together!
About BioConnection
BioConnection (BCO) is a specialized contract manufacturing organization (specialized CMO) serving the pharmaceutical industry. Operating from our FDA and EMA-certified facility in Oss, North Brabant, we specialize in producing injectable (bio)pharmaceutical products. Our services cover Chemistry, Manufacturing, and Controls (CMC), including drug product manufacturing process development, Fill & Finish for liquid, and freeze-drying (lyophilization) in vials and syringes. We also provide specialized small-scale (hand fill) production for personalized medicines, ensuring precision and flexibility.
At BioConnection, we support the entire drug life cycle, from producing materials for toxicology studies to clinical material manufacturing (Phase I-III) and final market production (up to 500 L). We excel in seamless project transitions, including internal technical transfers, scale-ups, and efficient preparation for Process Performance Qualification (PPQ) campaigns before market launch.
Ultimately, BioConnection drives healthcare innovation through strategic collaborations and emerging trend partnerships. While we do not engage in pharmacovigilance, our drug products are manufactured to meet strict quality standards that support this crucial aspect of the drug life cycle. We are committed to global health initiatives and sustainable manufacturing practices, improving access to life-saving medicines worldwide. Therefore, we would be delighted to discuss how we can support your projects.